Cited by 294Retinal Diseases and TreatmentsComplement system in diseasesOcular Diseases and Behçet’s Syndrome

Plasma complement components and activation fragments: Associations with age-related macular degeneration genotypes and phenotypes

Open access
Reynolds, Robyn, Hartnett, M. Elizabeth, Atkinson, John P., Giclas, Patricia C., Rosner, Bernard, Seddon, Johanna M.·2009·Investigative Opthalmology & Visual Science

Abstract

PURPOSE: Several genes encoding complement system components and fragments are associated with age-related macular degeneration (AMD). This study was conducted to determine whether alterations in circulating levels of these markers of complement activation and regulation are also independently associated with advanced AMD and whether they are related to AMD genotypes. METHODS: Plasma and DNA samples were selected from individuals in our AMD registry who had progressed to or developed the advanced stages of AMD, including 58 with geographic atrophy and 62 with neovascular disease. Subjects of similar age and sex, but without AMD, and who did not progress were included as controls (n = 60). Plasma complement components (C3, CFB, CFI, CFH, and factor D) and activation fragments (Bb, C3a, C5a, iC3b, and SC5b-9) were analyzed. DNA samples were genotyped for seven single-nucleotide polymorphisms in six genes previously shown to be associated with AMD: CFB, CFH, C2, C3, and CFI and the LOC387715/ARMS2 gene region. The association between AMD and each complement biomarker was assessed by using logistic regression, controlling for age, sex, and proinflammatory risk factors: smoking and body mass index (BMI). Functional genomic analyses were performed to assess the relationship between the complement markers and genotypes. Concordance, or C, statistics were calculated to assess the effect of complement components and activation fragments in an AMD gene-environment prediction model. RESULTS: The highest quartiles of Bb and C5a were significantly associated with advanced AMD, when compared with the lowest quartiles. In multivariate models without genetic variants, the odds ratio (OR) for Bb was 3.3 (95% confidence interval [CI] = 1.3-8.6), and the OR for C5a was 3.6 (95% CI = 1.2-10.3). With adjustment for genetic variants, these ORs were substantially higher. The alternative pathway regulator CFH was inversely associated with AMD in the model without genotypes (OR = 0.3; P = 0.01). Positive associations were found between BMI and plasma C3, CFB, CFH, iC3b, and C3a. There were also significant associations between C5a fragment and LOC387715/ARMS2 and C3 genotypes (P for trend = 0.02, 0.04), respectively. C statistics for models with behavioral and genetic factors increased to 0.94 +/- 0.20 with the addition of C3a, Bb, and C5a. CONCLUSIONS: Increased levels of activation fragments Bb and C5a are independently associated with AMD. Higher BMI is related to increased levels of complement components. C5a is associated with AMD genotypes. C statistics are stronger with the addition of C3a, Bb, and C5a in predictive models. Results implicate ongoing activation of the alternative complement pathway in AMD pathogenesis.

Integrity signals

Registry

Crossref · 10.1167/iovs.09-3928

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Reynolds, R., Hartnett, M. E., Atkinson, J. P., Giclas, P. C., Rosner, B., & Seddon, J. M.
Affiliations
  • Tufts University (US)
  • University of North Carolina at Chapel Hill (US)
  • Washington University in St. Louis (US)
  • National Jewish Health (US)
  • Brigham and Women's Hospital (US)
Venue
Investigative Opthalmology & Visual Science
Published
2009-12-01
Volume
50
Issue
12
Pages
5818
ISSN
  • 0146-0404 (ISSN-L)
  • 1552-5783
OpenAlex
W1994797655
Cited by
294
References
40
Citations by year
2026: 5 · 2025: 9 · 2024: 11 · 2023: 10 · 2022: 15 · 2021: 29 · 2020: 22 · 2019: 14 · 2018: 21 · 2017: 21 · 2016: 14 · 2015: 20 · 2014: 23 · 2013: 22 · 2012: 20
FWCI
19.67
Type
journal article
Language
en
Open access
Locations
  • Investigative Ophthalmology & Visual Science (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Eye Institute (R01 EY 11309, R01EY013982, R01EY011309)
  • National Institute of Allergy and Infectious Diseases (R01AI037618)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
Keywords
age-related macular degeneration, complement system, complement regulation, C5a, C3a, complement C3, complement factor H, CFB, CFI, factor D, Bb, iC3b, single nucleotide polymorphisms, geographic atrophy, neovascular AMD, body mass index
MeSH terms
Aged, Aged, 80 and over, Complement System Proteins, Complement Pathway, Alternative, Complement C2, Complement C3, Enzyme-Linked Immunosorbent Assay, Female, Genotype, Humans, Macular Degeneration, Male, Phenotype, Complement Factor B, Proteins, Body Mass Index, Complement Factor H, Complement Factor I, Polymorphism, Single Nucleotide

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review